Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-Outcomes study of orforglipron in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease
NL-OMON60600Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in atherosclerotic disease and chronic kidney disease (CKD) comparing Orforglipron with Placebo (2 arms). Primary endpoint: Time to first occurrence of composite major cardiovascular events endpoint. Started Jun 2026; status: recruiting.
02
Drugs
orforglipron
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON60600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60600.